Abstract
The efficacy of treatments for osteoporosis does not become evident when evaluated by fracture incidence (FI). Vertebral FI decreased in all controlled studies on calcitonin, but not significantly. Small sample sizes and short periods of treatment may have masked a possible therapeutic benefit, but longer, controlled studies with sodium fluoride or etidronate in larger groups of patients also failed to show a decrease in FI. The present analysis of nine published, therapeutic studies which indicate the FI per year and the initial prevalence of vertebral fractures, examines the question of whether the initial prevalence of fractures has an effect on the subsequent incidence of new fractures and whether the therapeutic effects have to be evaluated as a function of the initial prevalence of fractures. Bearing in mind the differences in roentgenological evaluation and in the size and quality of the various studies, the analysis revealed (1) that in the control groups there was a higher FI in patients with more than three vertebral fractures at baseline (estimated odds ratio (OR)=49,p=0.011); (2) that a similar trend, although not statistically significant, was observed in treated patients; (3) that the groups of control patients treated for more than 1 year showed in general an increase in FI beyond the first year and that the reverse was true in treated patients. In conclusion, failure to allow for the initial prevalence of vertebral fractures at the individual level in therapeutic trials of calcitonin to treat osteoporosis and prevent new fractures might have contributed to the absence of a demonstrable benefit of the treatment in those studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heaney RP, Baylink DJ, Johnston CC, Melton III LJ, Meunier PJ, Murray TM, et al. Fluoride therapy for the vertebral crush fracture syndrome. Ann Intern Med 1989;lll:678–80.
Agrawal RA, Cohn S, Tessier M, Verch R, Hussain M, Zanzi I. Calcitonin treatment of osteoporosis. In: Calcitonin 1980. Proceedings of an international symposium, Milan, Oct. 1980. Amsterdam: Excerpta Medica, 1981:237–46.
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984;33:295–303.
Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonnelli S, Ferrara R, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38:455–64.
Ringe JD. Behandlung der primären Osteoporose mit Calcium und Lachscalcitonin. Dtsch Med Wochenschr 1990;115:1176–82.
Peyron R, Serrurier D, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ, CIGOP. Treatment of high remodeling vertebral osteoporosis with human calcitonin: a two-year double-blind placebo-controlled trial in 93 patients. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress ApS. 1990:1430–3.
Riggs BL, Hodgson SF, O'Fallon W, Chao EYS, Wahner HW, Muhs JM, et al. Effect of fluoride treatment of the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.
Kleerekoper M, Peterson E, Phillips E, Nelson D, Tilley B, Parfitt AM. Continuous sodium fluoride therapy does not reduce vertebral fracture rate in postmenopausal osteoporosis. J Bone Miner Res 1989;4 Suppl 1:S376.
Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.
Storm T, Thamsborg G, Steinicke T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.
Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982; 306:446–50.
Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;3:361–5.
Pak CYC, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989;68: 150–9.
Murray TM, Harrison JE, Bayley TA, Josse RG, Sturtridge WC, Chow R, et al. Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response. J Bone Miner Res 1990;5 Suppl 1:S27-S35.
Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malhem J, Maldague B. Treatment of vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements. J Bone Miner Res 1990:5 Suppl 1:S5–26.
Bucket RM. Three year study of sodium fluoride treatment on vertebral fracture incidence in osteoporosis. J Bone Miner Res 1989;4 Suppl 1:S186.
Serrurier D, Peyron R, Edouard C, Ghozlan R, Mayoux-Benhamou A, Meunier PJ, CIGOP. Treatment of vertebral osteoporosis: a two year comparative trial of coherence therapy (ADFR) versus sodium fluoride in 75 patients without hyperremodeling. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990:1434–7.
Kanis JA. Treatment of osteoporotic fracture. Lancet 1984; 1:27–33.
Ross PD, Wasnich RD, Davis JW. Fracture prediction models for osteoporosis prevention. Bone 1990;11:327–31.
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures in bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23.
Dambacher MA, Ittner J, Rüegsegger P. Long-term fluoride therapy of postmenopausal osteoporosis. Bone 1986;7: 199–205.
Chalmers TC, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981;2:31–49.
Clemens JD, Chuong JJM, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983;249:2362–9.
Gerbarg ZB, Horwitz RI. Resolving conflicting trials: guidelines for meta-analysis. J Clin Epidemiol 1988;41:503–9.
Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia: WB Saunders, 1985.
Dean AD, Dean JA, Burton JH, Dicker RC. Epi Info, version 5: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control, Atlanta, GA, 1990.
Haldane JBS. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Gene 1955;20:309–14.
Arnold JS. Focal excessive endosteal resorption in ageing and sterile osteoporosis. In: Barzel US, editor. Osteoporosis. New York: Grune and Stratton, 1970:80–100.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burckhardt, P., Burnand, B. The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis. Osteoporosis Int 3, 24–30 (1993). https://doi.org/10.1007/BF01623173
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01623173